Moderna’s Strong Vaccine Sales Outside US Far Surpass Estimates

Moderna Inc.’s first-quarter sales beat expectations, as the struggling vaccine maker that’s faced resistance from the Trump administration has found new growth outside the US.

First-quarter sales more than tripled from a year ago to $389 million, well above the highest analyst estimate for $333 million. The sharp increase was fueled by deals that Moderna has made with governments outside the US, including its first shipment to the UK under a new long-term agreement.